In this study, we reported on the preclinical characterization of 293C3-SDIE, a chimerized and Fc-optimized mAb targeting CD133 for the treatment of B-ALL. The gene discussed is PROM1; the disease is precursor B-cell acute lymphoblastic leukemia.